Victory Capital Management Inc. Has $55.50 Million Position in Exact Sciences Co. (NASDAQ:EXAS)

Victory Capital Management Inc. increased its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 47.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 750,228 shares of the medical research company’s stock after buying an additional 239,840 shares during the period. Victory Capital Management Inc. owned about 0.41% of Exact Sciences worth $55,502,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC raised its position in Exact Sciences by 459.5% during the 4th quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after purchasing an additional 340 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Exact Sciences in the third quarter valued at about $33,000. Cullen Frost Bankers Inc. raised its position in shares of Exact Sciences by 40.0% during the third quarter. Cullen Frost Bankers Inc. now owns 700 shares of the medical research company’s stock worth $48,000 after acquiring an additional 200 shares during the last quarter. Valley National Advisers Inc. lifted its stake in shares of Exact Sciences by 29.5% in the third quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after acquiring an additional 176 shares during the period. Finally, Milestone Investment Advisors LLC bought a new stake in Exact Sciences in the third quarter valued at approximately $57,000. 88.82% of the stock is owned by institutional investors.

Exact Sciences Stock Up 2.5 %

NASDAQ:EXAS opened at $62.07 on Friday. Exact Sciences Co. has a 1 year low of $56.05 and a 1 year high of $100.77. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. The business has a fifty day simple moving average of $63.37 and a two-hundred day simple moving average of $64.75.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.26. The business had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company’s revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.72) earnings per share. On average, analysts anticipate that Exact Sciences Co. will post -0.86 earnings per share for the current year.

Insider Activity at Exact Sciences

In other Exact Sciences news, insider Jacob A. Orville sold 966 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $59,341.38. Following the sale, the insider now owns 7,488 shares in the company, valued at $459,987.84. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Exact Sciences news, insider Jacob A. Orville sold 966 shares of Exact Sciences stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $59,341.38. Following the completion of the transaction, the insider now owns 7,488 shares of the company’s stock, valued at approximately $459,987.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jacob A. Orville sold 1,078 shares of the stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $61.50, for a total transaction of $66,297.00. Following the completion of the sale, the insider now directly owns 8,658 shares in the company, valued at $532,467. The disclosure for this sale can be found here. In the last ninety days, insiders sold 70,611 shares of company stock worth $4,255,377. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EXAS. TheStreet cut shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Citigroup reissued a “buy” rating and issued a $100.00 price objective on shares of Exact Sciences in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group decreased their target price on Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $97.44.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.